Ginkgo Bioworks Holdings, Inc. 8-K

What Happened
Ginkgo Bioworks Holdings, Inc. (DNA) announced its financial results for the fourth quarter 2025 and the year ended December 31, 2025 via a press release dated February 26, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The Form 8-K was signed by Steven Coen, Chief Financial Officer, on February 26, 2026.

Key Details

• Filed Form 8-K on February 26, 2026 to disclose Q4 2025 and full-year 2025 results (Item 2.02).
• Press release announcing the results is furnished as Exhibit 99.1.
• Cover page interactive data (Inline XBRL) is included as Exhibit 104.
• Form 8-K signed by Steven Coen, CFO, on February 26, 2026.

Why It Matters
This filing formally makes Ginkgo’s quarterly and annual earnings and related commentary available to investors and the market. Retail investors should read the furnished press release for details on revenue, earnings or losses, cash flow and any management commentary or outlook, as those figures can directly affect the stock and investor decisions. Also watch for any accompanying filings (e.g., 10-K, earnings presentation or call) that typically provide more detailed financial statements and analysis.